Advanced in Pure Red Cell Aplasia

Dr. Jeremie H. Estepp

Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Pure Red Cell Aplasia
262 Danny Thomas Pl, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremie Estepp is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Estepp is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Pure Red Cell Aplasia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

262 Danny Thomas Pl, Memphis, TN 38105

Additional Areas of Focus

Dr. Estepp has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Investigation of the Genetics of Hematologic Diseases
Investigation of the Genetics of Hematologic Diseases
Enrollment Status: Recruiting
Publish Date: May 11, 2025
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Enrollment Status: No_longer_available
Publish Date: November 20, 2024
Intervention Type: Drug
SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study
SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study
Enrollment Status: Completed
Publish Date: August 12, 2024
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Enrollment Status: Terminated
Publish Date: March 18, 2022
Intervention Type: Drug
Study Drugs: Hydroxyurea, Hydroxyurea Oral Capsule
Study Phase: Phase 2
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Enrollment Status: Completed
Publish Date: June 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

57 Total Publications

Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: November 08, 2024
Similar Doctors
Elite in Pure Red Cell Aplasia
Dr. Marcin W. Wlodarski
Pediatric Hematology Oncology
Elite in Pure Red Cell Aplasia
Dr. Marcin W. Wlodarski
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
888-226-4343
Languages Spoken:
English
See accepted insurances

Marcin Wlodarski is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Wlodarski is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Dyskeratosis Congenita, Bone Marrow Transplant, and Splenectomy.

Distinguished in Pure Red Cell Aplasia
Dr. Mitchell J. Weiss
Pediatric Hematology Oncology
Distinguished in Pure Red Cell Aplasia
Dr. Mitchell J. Weiss
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-3006
Languages Spoken:
English
See accepted insurances

Mitchell Weiss is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Weiss is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Anemia, Sickle Cell Disease, Hemoglobinopathy, Adenoidectomy, and Bone Marrow Transplant.

Advanced in Pure Red Cell Aplasia
Dr. Shruthi Suryaprakash
Pediatric Hematology Oncology
Advanced in Pure Red Cell Aplasia
Dr. Shruthi Suryaprakash
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-3300
Languages Spoken:
English
See accepted insurances

Shruthi Suryaprakash is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Suryaprakash is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Aase Syndrome, X-Linked Lymphoproliferative Disease, Pure Red Cell Aplasia, and Transient Erythroblastopenia of Childhood.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Estepp's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile